Successful Portfolios LLC Purchases 68 Shares of Danaher Co. (NYSE:DHR)

Successful Portfolios LLC grew its holdings in shares of Danaher Co. (NYSE:DHR) by 6.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,107 shares of the conglomerate’s stock after purchasing an additional 68 shares during the quarter. Successful Portfolios LLC’s holdings in Danaher were worth $256,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. DHJJ Financial Advisors Ltd. purchased a new position in Danaher during the 3rd quarter worth $25,000. BKM Wealth Management LLC acquired a new stake in shares of Danaher during the fourth quarter worth about $27,000. OFI Invest Asset Management acquired a new position in shares of Danaher in the 3rd quarter valued at $30,000. First Capital Advisors Group LLC. acquired a new position in Danaher during the second quarter worth $32,000. Finally, BOK Financial Private Wealth Inc. acquired a new position in Danaher during the third quarter worth about $34,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In other news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the transaction, the senior vice president now owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock worth $8,265,802 over the last three months. 11.10% of the stock is currently owned by insiders.

Danaher Price Performance

Danaher stock traded up $0.95 during mid-day trading on Thursday, reaching $249.72. The company had a trading volume of 2,472,006 shares, compared to its average volume of 2,762,914. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00. The business has a fifty day simple moving average of $247.17 and a 200 day simple moving average of $230.53. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. The company has a market cap of $184.72 billion, a P/E ratio of 39.21, a P/E/G ratio of 3.77 and a beta of 0.84.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.18. The business had revenue of $6.41 billion for the quarter, compared to analysts’ expectations of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The firm’s revenue for the quarter was down 10.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.87 EPS. On average, equities research analysts predict that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date is Wednesday, March 27th. Danaher’s dividend payout ratio (DPR) is 15.02%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on DHR shares. HSBC began coverage on shares of Danaher in a research note on Monday, December 18th. They issued a “hold” rating for the company. Barclays downgraded Danaher from an “overweight” rating to an “equal weight” rating and set a $240.00 price target on the stock. in a research note on Wednesday, January 24th. The Goldman Sachs Group cut Danaher from a “buy” rating to a “neutral” rating and dropped their price target for the company from $215.00 to $205.00 in a research report on Thursday, December 7th. KeyCorp lifted their price objective on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Finally, TheStreet upgraded Danaher from a “c+” rating to a “b-” rating in a research report on Friday, December 8th. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $266.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.